Hong Kong · Delayed Price · Currency is HKD InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 30.91 billion. The enterprise value is 24.93 billion.
| Market Cap | 30.91B |
| Enterprise Value | 24.93B |
Important Dates
The next confirmed earnings date is Monday, August 24, 2026.
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.70 billion shares outstanding. The number of shares has decreased by -0.97% in one year.
| Current Share Class | 1.43B |
| Shares Outstanding | 1.70B |
| Shares Change (YoY) | -0.97% |
| Shares Change (QoQ) | -8.70% |
| Owned by Insiders (%) | 20.54% |
| Owned by Institutions (%) | 31.51% |
| Float | 1.13B |
Valuation Ratios
The trailing PE ratio is 29.71 and the forward PE ratio is 106.46.
| PE Ratio | 29.71 |
| Forward PE | 106.46 |
| PS Ratio | 10.78 |
| PB Ratio | 3.69 |
| P/TBV Ratio | 3.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 860.64 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 30.03 |
| EV / Sales | 8.70 |
| EV / EBITDA | 33.41 |
| EV / EBIT | 40.16 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.65, with a Debt / Equity ratio of 0.25.
| Current Ratio | 5.65 |
| Quick Ratio | 5.23 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 2.76 |
| Debt / FCF | -41.58 |
| Interest Coverage | 9.93 |
Financial Efficiency
Return on equity (ROE) is 10.36% and return on invested capital (ROIC) is 24.59%.
| Return on Equity (ROE) | 10.36% |
| Return on Assets (ROA) | 3.45% |
| Return on Invested Capital (ROIC) | 24.59% |
| Return on Capital Employed (ROCE) | 6.11% |
| Weighted Average Cost of Capital (WACC) | 6.17% |
| Revenue Per Employee | 2.44M |
| Profits Per Employee | 705,891 |
| Employee Count | 1,176 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 1.61 |
Taxes
In the past 12 months, InnoCare Pharma has paid 13.69 million in taxes.
| Income Tax | 13.69M |
| Effective Tax Rate | 1.62% |
Stock Price Statistics
The stock price has decreased by -26.18% in the last 52 weeks. The beta is 0.39, so InnoCare Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -26.18% |
| 50-Day Moving Average | 13.20 |
| 200-Day Moving Average | 13.14 |
| Relative Strength Index (RSI) | 57.39 |
| Average Volume (20 Days) | 7,331,432 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 2.87 billion and earned 830.13 million in profits. Earnings per share was 0.49.
| Revenue | 2.87B |
| Gross Profit | 2.62B |
| Operating Income | 620.76M |
| Pretax Income | 845.90M |
| Net Income | 830.13M |
| EBITDA | 712.18M |
| EBIT | 620.76M |
| Earnings Per Share (EPS) | 0.49 |
Balance Sheet
The company has 8.06 billion in cash and 2.06 billion in debt, with a net cash position of 6.00 billion or 3.54 per share.
| Cash & Cash Equivalents | 8.06B |
| Total Debt | 2.06B |
| Net Cash | 6.00B |
| Net Cash Per Share | 3.54 |
| Equity (Book Value) | 8.37B |
| Book Value Per Share | 4.73 |
| Working Capital | 7.67B |
Cash Flow
In the last 12 months, operating cash flow was 35.92 million and capital expenditures -85.41 million, giving a free cash flow of -49.49 million.
| Operating Cash Flow | 35.92M |
| Capital Expenditures | -85.41M |
| Depreciation & Amortization | 93.79M |
| Net Borrowing | 263.69M |
| Free Cash Flow | -49.49M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 91.36%, with operating and profit margins of 21.65% and 28.95%.
| Gross Margin | 91.36% |
| Operating Margin | 21.65% |
| Pretax Margin | 29.51% |
| Profit Margin | 28.95% |
| EBITDA Margin | 24.84% |
| EBIT Margin | 21.65% |
| FCF Margin | n/a |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.61% |
| Buyback Yield | 0.97% |
| Shareholder Yield | 0.97% |
| Earnings Yield | 2.69% |
| FCF Yield | -0.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for InnoCare Pharma is 20.02, which is 36.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 20.02 |
| Price Target Difference | 36.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 15.76% |
| EPS Growth Forecast (3Y) | -3.90% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 5.42 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.42 |
| Piotroski F-Score | 6 |